Thomas CIVIK

MBA Independent Chairman

Thomas Civik’s most recent corporate position was as CEO and President of Five Prime Therapeutics, where he oversaw the clinical development of the company’s oncology pipeline and the acquisition by Amgen in 2021. Prior to that, he was the Chief Commercial Officer at Foundation Medicine and led the launch of the first-ever, FDA-approved pan-cancer comprehensive genomic test. 
Mr. Civik had a distinguished 17-year career at Genentech, lastly as Vice President and Franchise Head, where he was responsible for the commercialization efforts for several leading oncology products generating more than $3 billion in revenue. Mr. Civik began his tenure at Genentech in the managed care area and held senior leadership positions focused on providing access for the entire Genentech portfolio. Prior to Genentech, Mr. Civik spent eight years at Sanofi in increasingly complex sales, sales management and account management roles.

Thomas Civik currently serves on the Board of Directors of Repare Therapeutics (as Chairman) and of Pyxis Oncology.
He holds an MBA from the Kellogg School of Management at Northwestern University.